Ensysce Biosciences (ENSC) vs Moleculin Biotech (MBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ensysce Biosciences is the larger company by market cap ($10.2 million vs $8.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENSC | MBRX |
|---|---|---|
| Share price | $0.5238 | $0.4299 |
| Market cap | $10.19M | $8.76M |
| 1-day change | +14.37% | +1.39% |
| P/E ratio (TTM) | — | 0.05 |
| EPS (TTM) | $-2.47 | $8.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.75 | $15.75 |
| 52-week low | $0.23 | $0.161 |
| Distance from 52-week high | -80.95% | -97.27% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1475.03% | +2691.35% |
| Average volume | 14.21M | 1.29M |
| Shares outstanding | 19.46M | 20.39M |
| Employees | 8 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ensysce Biosciences
ENSC stock →Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Moleculin Biotech
MBRX stock →Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
ENSC vs MBRX FAQ
Which is bigger, Ensysce Biosciences or Moleculin Biotech?
Ensysce Biosciences (ENSC) is larger, with a market capitalization of $10.19M compared with $8.76M for Moleculin Biotech (MBRX).
Are Ensysce Biosciences and Moleculin Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.